Multidisciplinary
Some of the hyperlinks provided are to sites of organizations or other entities that are not subject to the Official Languages Act. The material found there is therefore in the language(s) used by the sites in question.
Should you have any questions or comments regarding the content of the guidance documents found on this page please contact:
Health Canada – ICH Coordinator
Email: hc.ich.sc@canada.ca
- M1 - MedDRA (Medical Dictionary for Regulatory Authorities)
- M3(R2): Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals [2016-01-21]
- M7: Guidance Document: Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk [2019-01-19]
- M9: Biopharmaceutics Classification System-based Biowaivers [2020-08-26]
Report a problem or mistake on this page
- Date modified: